Overview

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Status:
COMPLETED
Trial end date:
2024-08-18
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
Phase:
PHASE2
Details
Lead Sponsor:
Navitor Pharmaceuticals, Inc.
Collaborator:
Supernus Pharmaceuticals, Inc.
Treatments:
NV-5138